Moleculin's Annamycin cardiac safety data accepted for ASCO poster presentation

Filed May 22, 2026 · Period ending May 22, 2026 · ~1 min read

Key Changes

• medium

  Pooled cardiac safety data for lead drug candidate Annamycin accepted for poster presentation at the 2026 ASCO Annual Meeting (May 29-June 2 in Chicago). Cardiac safety is a key concern for oncology drugs.

  Item 7.01 verify on EDGAR →
• medium

  The abstract features data for Annamycin (also called L-Annamycin or naxtarubicin), the company's lead drug candidate currently in clinical development.

  Press Release verify on EDGAR →